Metabolic tumor volume from baseline 18 FFDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma

Although several different parameters of PET/CT were reported to be predictive of survival in DLBCL, the best parameter remains to be elucidated and whether it could improve the risk stratification of IPI in patients with DLBCL.PURPOSEAlthough several different parameters of PET/CT were reported to...

Full description

Saved in:
Bibliographic Details
Published inAnnals of hematology
Main Authors Zhang, Hanzhen, Xu, Zihan, Zhou, Wenlan, Chen, Junjie, Wei, Yongqiang, Wu, Hubing, Wei, Xiaolei, Feng, Ru
Format Journal Article
LanguageEnglish
Published 02.09.2024
Online AccessGet full text

Cover

Loading…
Abstract Although several different parameters of PET/CT were reported to be predictive of survival in DLBCL, the best parameter remains to be elucidated and whether it could improve the risk stratification of IPI in patients with DLBCL.PURPOSEAlthough several different parameters of PET/CT were reported to be predictive of survival in DLBCL, the best parameter remains to be elucidated and whether it could improve the risk stratification of IPI in patients with DLBCL.262 DLBCL patients including in the training and validation cohort were retrospectively analyzed in this study.PROCEDURES262 DLBCL patients including in the training and validation cohort were retrospectively analyzed in this study.Among different parameters, MTV was identified as the optimal prognostic parameter with a maximum area under the curve (AUC) of 0.652 ± 0.112 than TLG and SDmax (0.645 ± 0.113 and 0.600 ± 0.117, respectively). Patients with high MTV were associated with inferior PFS (p < 0.001 and p = 0.021, respectively) and OS (p < 0.001 and p < 0.001, respectively) in both the training and validation cohort. The multivariate analysis revealed that high MTV was an unfavorable factor for PFS (relative ratio [RR], 2.295; 95% confidence interval [CI], 1.457-3.615; p < 0.01) and OS (RR, 2.929; 95% CI 1.679-5.109; p < 0.01) independent of IPI.RESULTSAmong different parameters, MTV was identified as the optimal prognostic parameter with a maximum area under the curve (AUC) of 0.652 ± 0.112 than TLG and SDmax (0.645 ± 0.113 and 0.600 ± 0.117, respectively). Patients with high MTV were associated with inferior PFS (p < 0.001 and p = 0.021, respectively) and OS (p < 0.001 and p < 0.001, respectively) in both the training and validation cohort. The multivariate analysis revealed that high MTV was an unfavorable factor for PFS (relative ratio [RR], 2.295; 95% confidence interval [CI], 1.457-3.615; p < 0.01) and OS (RR, 2.929; 95% CI 1.679-5.109; p < 0.01) independent of IPI.Further analysis showed MTV could improve the risk stratification of IPI for both PFS and OS (p < 0.01 and p < 0.01, respectively). In conclusion, our study suggests that MTV was an optimal prognostic parameter of PET/CT for survival and it could improve the risk stratification of IPI in DLBCL, which may help to guide treatment in clinical trial.CONCLUSIONSFurther analysis showed MTV could improve the risk stratification of IPI for both PFS and OS (p < 0.01 and p < 0.01, respectively). In conclusion, our study suggests that MTV was an optimal prognostic parameter of PET/CT for survival and it could improve the risk stratification of IPI in DLBCL, which may help to guide treatment in clinical trial.
AbstractList Although several different parameters of PET/CT were reported to be predictive of survival in DLBCL, the best parameter remains to be elucidated and whether it could improve the risk stratification of IPI in patients with DLBCL.PURPOSEAlthough several different parameters of PET/CT were reported to be predictive of survival in DLBCL, the best parameter remains to be elucidated and whether it could improve the risk stratification of IPI in patients with DLBCL.262 DLBCL patients including in the training and validation cohort were retrospectively analyzed in this study.PROCEDURES262 DLBCL patients including in the training and validation cohort were retrospectively analyzed in this study.Among different parameters, MTV was identified as the optimal prognostic parameter with a maximum area under the curve (AUC) of 0.652 ± 0.112 than TLG and SDmax (0.645 ± 0.113 and 0.600 ± 0.117, respectively). Patients with high MTV were associated with inferior PFS (p < 0.001 and p = 0.021, respectively) and OS (p < 0.001 and p < 0.001, respectively) in both the training and validation cohort. The multivariate analysis revealed that high MTV was an unfavorable factor for PFS (relative ratio [RR], 2.295; 95% confidence interval [CI], 1.457-3.615; p < 0.01) and OS (RR, 2.929; 95% CI 1.679-5.109; p < 0.01) independent of IPI.RESULTSAmong different parameters, MTV was identified as the optimal prognostic parameter with a maximum area under the curve (AUC) of 0.652 ± 0.112 than TLG and SDmax (0.645 ± 0.113 and 0.600 ± 0.117, respectively). Patients with high MTV were associated with inferior PFS (p < 0.001 and p = 0.021, respectively) and OS (p < 0.001 and p < 0.001, respectively) in both the training and validation cohort. The multivariate analysis revealed that high MTV was an unfavorable factor for PFS (relative ratio [RR], 2.295; 95% confidence interval [CI], 1.457-3.615; p < 0.01) and OS (RR, 2.929; 95% CI 1.679-5.109; p < 0.01) independent of IPI.Further analysis showed MTV could improve the risk stratification of IPI for both PFS and OS (p < 0.01 and p < 0.01, respectively). In conclusion, our study suggests that MTV was an optimal prognostic parameter of PET/CT for survival and it could improve the risk stratification of IPI in DLBCL, which may help to guide treatment in clinical trial.CONCLUSIONSFurther analysis showed MTV could improve the risk stratification of IPI for both PFS and OS (p < 0.01 and p < 0.01, respectively). In conclusion, our study suggests that MTV was an optimal prognostic parameter of PET/CT for survival and it could improve the risk stratification of IPI in DLBCL, which may help to guide treatment in clinical trial.
Author Feng, Ru
Wei, Yongqiang
Zhang, Hanzhen
Xu, Zihan
Chen, Junjie
Wu, Hubing
Wei, Xiaolei
Zhou, Wenlan
Author_xml – sequence: 1
  givenname: Hanzhen
  surname: Zhang
  fullname: Zhang, Hanzhen
– sequence: 2
  givenname: Zihan
  surname: Xu
  fullname: Xu, Zihan
– sequence: 3
  givenname: Wenlan
  surname: Zhou
  fullname: Zhou, Wenlan
– sequence: 4
  givenname: Junjie
  surname: Chen
  fullname: Chen, Junjie
– sequence: 5
  givenname: Yongqiang
  surname: Wei
  fullname: Wei, Yongqiang
– sequence: 6
  givenname: Hubing
  surname: Wu
  fullname: Wu, Hubing
– sequence: 7
  givenname: Xiaolei
  surname: Wei
  fullname: Wei, Xiaolei
– sequence: 8
  givenname: Ru
  surname: Feng
  fullname: Feng, Ru
BookMark eNqVjb1OwzAUhS1UJFrgBZjuyBJqJylOVkoDHZA6ZK_ccNMY-Sf4OkU8Ba-MkRhYWc6PdD6dBZs575CxG8HvBOdySZznUmY8LzO-kkJm9Rmbi7LIU63K2Z98wRZEb5yLvCrzOft6wagO3ugO4mR9gJM3k0Xog7dwUIRGOwRRQdM8PsFu0y7XLagIr1odnSdNoO0Y_AkJ4oCw3W2BYlBR97pL6h1oB2NK6CLBh45DQvt-IgSjwhHhIevQGDCfdhy8VVfsvFeG8PrXL9lts2nXz1k6eZ-Q4t5q-iGUQz_RvuB1Xd0XKyGLf0y_Ace1YWs
ContentType Journal Article
Copyright 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright_xml – notice: 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
DBID 7X8
DOI 10.1007/s00277-024-05717-9
DatabaseName MEDLINE - Academic
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-0584
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-~C
-~X
.86
.VR
06C
06D
0R~
0VY
199
1N0
203
23M
29~
2J2
2JN
2JY
2KG
2KM
2LR
2~H
30V
36B
4.4
406
408
409
40D
40E
5GY
5RE
5VS
67Z
6NX
78A
7RV
7X8
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABUWZ
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFJLC
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BENPR
BGNMA
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
EBLON
EBS
EIOEI
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FNLPD
FRRFC
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
HF~
HG5
HG6
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
LAS
LLZTM
M4Y
MA-
N9A
NB0
NPVJJ
NQJWS
NU0
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PT4
PT5
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNS
ROL
RPX
RRX
RSV
S16
S1Z
S27
S37
S3B
SAP
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZ9
SZN
T13
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZMTXR
ZOVNA
~EX
~KM
ID FETCH-proquest_miscellaneous_30998635173
ISSN 1432-0584
IngestDate Sat Oct 26 04:10:57 EDT 2024
IsPeerReviewed true
IsScholarly true
Language English
LinkModel OpenURL
MergedId FETCHMERGED-proquest_miscellaneous_30998635173
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-2
PQID 3099863517
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3099863517
PublicationCentury 2000
PublicationDate 20240902
PublicationDateYYYYMMDD 2024-09-02
PublicationDate_xml – month: 09
  year: 2024
  text: 20240902
  day: 02
PublicationDecade 2020
PublicationTitle Annals of hematology
PublicationYear 2024
SSID ssj0012842
Score 4.8786373
Snippet Although several different parameters of PET/CT were reported to be predictive of survival in DLBCL, the best parameter remains to be elucidated and whether it...
SourceID proquest
SourceType Aggregation Database
Title Metabolic tumor volume from baseline 18 FFDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma
URI https://www.proquest.com/docview/3099863517
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1LS8NAEMcXHyBexCc-ywgehLBqk7RJjrY2VrG1SMTgpTTNhlZqAm1y0C_hV3Z2N49KBB-XtCwhoZ0fs7Oz858l5OTCDyxND3RaZ6pGdd-rU8vzLMp0o87LdIdVcVpDp1tvP-q3bs0tSnmFuiT2zobv3-pK_mNVHEO7cpXsHyybPxQH8DvaF69oYbz-ysYdFqMNeZvqOHmNpop0NVIywqcnEUJWTcW2r66VXsvhzXAdLl_0ZYHdeMZVktOId54VVZS9G0X20Q3SVJ5StF5NdXD8RJVkxpQJLyFXGpRn_pXJG0IRpS6-1JpZ9IX9kr7P09RtDE1HhRrNTcRmyXhUMPs8isTgEwsnxWgzF5WEL2M2n7pQdVGbNZfNxFhNpRc1eUbcGSuPlfy7LOngR2kZBhVPrOF6lFrFbJbt4Hfv-_bj3V3fabnOIllW0Q-hA1y-tBuNbr7NhHOz2A7P3pmqqoS2svSO0mwtQhBnnaylawe4lCBskAUWbpKVTlodsUU-ch5A8ACSB-A8QMYDVE3gPADycN50YBBDTgNkNADSAEgDfKUBxiFkNACnAVIaQNAAkgbIaNgmp3bLabZp9oP66FT4HYOQRcmsr-G6wcRQtGpoO2QpjEK2SyBgnskwftQ8Zuo1AxcW-D8NLM331SAwhvoeOf7xcfu_uOeArBawHJKleJqwI4z8Yq9CFg3XqKRWxM9Gq9t7-AQWDWNw
link.rule.ids 315,783,787,27936,27937,31732,33757
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolic+tumor+volume+from+baseline+18+FFDG+PET%2FCT+at+diagnosis+improves+the+IPI+stratification+in+patients+with+diffuse+large+B-cell+lymphoma&rft.jtitle=Annals+of+hematology&rft.au=Zhang%2C+Hanzhen&rft.au=Xu%2C+Zihan&rft.au=Zhou%2C+Wenlan&rft.au=Chen%2C+Junjie&rft.date=2024-09-02&rft.issn=1432-0584&rft.eissn=1432-0584&rft_id=info:doi/10.1007%2Fs00277-024-05717-9&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1432-0584&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1432-0584&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1432-0584&client=summon